Compare Eli Lilly And Co (LLY) vs ProShares Ultra QQQ ETF (QLD) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

QLD, the ProShares Ultra QQQ ETF, trades at $86.06, up 0.17% on the day. The technical outlook is bearish, with moving averages signaling a downtrend and key support at $85. Recent articles highlight its long-term performance, with over 10,000% total return since inception, but caution its leveraged structure amplifies risks, evidenced by a historical maximum drawdown exceeding 63%.

The outlook for QLD is heavily tied to the performance of the Nasdaq-100 index. While leveraged exposure offers potential for amplified gains during tech rallies, the daily reset mechanism poses significant volatility and decay risks in choppy markets. Investor focus remains on upcoming tech earnings and broader market trends for directional cues.